Stockreport

Immunome: Upcoming NDA, Valuation, And Investment Case [Seeking Alpha]

Immunome, Inc.  (IMNM) 
PDF Varegacestat demonstrated superior efficacy and safety versus nirogacestat, with an 84% risk reduction in progression or death and a 56% objective response rate. Desp [Read more]